On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) expressed a positive opinion for the Dengue Tetravalent Vaccine (Live, Attenuated). This vaccine is used for the prevention of dengue disease, including lowering the risk of hospitalisation, in individuals from 4 years of age.
In the meantime, regulatory reviews about this Dengue Tetravalent Vaccine are also in progress in Latin America and Asia.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
